Skip to main content

Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study

Abstract

The purpose of this study was to determine the safety and efficacy of botulinum toxin type A (BOTOX; Allergan, Irvine, USA) in migraine prophylaxis. We performed a double-blind, randomized, 90-day placebo-controlled study that enrolled 30 adult migraineurs. Patients received 50 units botulinum toxin type A (n=15) or placebo (n=15). Outcome measures were monthly frequency and duration of migraine attacks and the number of severe attacks. Botulinum toxin type A produced significantly greater reductions in the frequency of migraine attacks of any severity at Day 90 (-3.14 vs. -0.53; p<0.05) and in the frequency of severe migraine attacks at Days 60 (-1.4 vs. -0.54; p<0.05) and 90 (-1.8 vs. -0.20; p<0.02). One patient in the botulinum toxin type A group experienced mild, transient frontalis muscle weakness lasting approximately 30 days. Botulinum toxin type A injections were well tolerated and provided effective migraine prophylaxis in these patients.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nelson Barrientos.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barrientos, N., Chana, P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 4, 146–151 (2003). https://doi.org/10.1007/s10194-003-0049-2

Download citation

Key words

  • Migraine
  • Botulinum toxin type A
  • Prophylaxis
  • Double blind
  • Placebo control